Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.
https://www.foxnews.com/health/fda-approves-once-daily-pill-deadly-cancer-patients-see-survival-nearly-double
https://www.foxnews.com/health/fda-approves-once-daily-pill-deadly-cancer-patients-see-survival-nearly-double